ATP Binding Cassette Transporter D1 (ABCD1) Antibody

Este producto es parte de ABCD - ATP Binding Cassette Transporter D
Product Graph
260€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
ATP Binding Cassette Transporter D1 (ABCD1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx130575
tested applications
WB, IHC, IF/ICC

Description

ABCD1 Antibody is a Rabbit Polyclonal against ABCD1.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
ATP Binding Cassette Transporter D1 (ABCD1)
Host
Rabbit
Reactivity
Human
Recommended Dilution
WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Purification
Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.
Size 1
100 µl
Size 2
200 µl
Size 3
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-7 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P33897
Alias
ABC42,ALD,ALDP,AMN,Adrenoleukodystrophy protein
Background
Antibody anti-ABCD1
Status
RUO

Descripción

ATP Binding Cassette Transporter D1 (ABCD1), part of the peroxisomal ABC transporter family, facilitates the import of very-long-chain fatty acids (VLCFAs) into peroxisomes for degradation. Mutations in the ABCD1 gene cause X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative disorder characterized by the accumulation of VLCFAs in the central nervous system, adrenal glands, and plasma. ABCD1 dysfunction leads to demyelination, adrenal insufficiency, and progressive neurological decline. The protein is ubiquitously expressed, with high levels in tissues involved in lipid metabolism, including the liver, adrenal glands, and brain. Therapies targeting ABCD1, such as gene therapy and dietary interventions to reduce VLCFA levels, have shown promise in mitigating disease progression. Its essential role in lipid homeostasis highlights its broader relevance in metabolic and peroxisomal disorders.

Related Products

FNab00035

ABCD1 antibody

Probable transporter. The nucleotide-binding fold acts as an ATP-binding subunit with ATPase activity.

Ver Producto
FNab00036

ABCD1 antibody

Probable transporter. The nucleotide-binding fold acts as an ATP-binding subunit with ATPase activity.

Ver Producto
FNab00037

ABCD1 antibody

Probable transporter. The nucleotide-binding fold acts as an ATP-binding subunit with ATPase activity.

Ver Producto